サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1785837

ビグアナイドの世界市場

Biguanides

出版日
ページ情報
英文 268 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
ビグアナイドの世界市場
出版日: 2025年08月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 268 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ビグアナイドの世界市場は2030年までに59億米ドルに到達

2024年に51億米ドルと推定されたビグアナイドの世界市場は、2024～2030年の分析期間においてCAGR 2.5%で成長し、2030年には59億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるメトホルミンは、CAGR 3.1%を記録し、分析期間終了時には35億米ドルに達すると予測されます。フェンホルミン・セグメントの成長率は、分析期間中CAGR 1.7%と推定されます。

米国市場は14億米ドルと推定、中国はCAGR 5.0％で成長予測

米国のビグアナイド市場は、2024年に14億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに11億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.9％と1.9％と予測されています。欧州では、ドイツがCAGR 1.4%で成長すると予測されています。

世界のビグアナイド市場- 主要動向と促進要因のまとめ

ビグアナイドが糖尿病や抗菌薬治療において重要な要素である理由とは？

ビグアナイドは、主に2型糖尿病の治療に使用される薬剤の一種で、血糖値を下げ、インスリン感受性を改善する効果があるため、糖尿病管理の要であり続けています。最も広く処方されているビグアナイド薬であるメトホルミンは、末梢でのグルコース取り込みを促進する一方で、肝でのグルコース産生を減少させるという役割で世界的に認知されています。世界的に2型糖尿病や代謝異常の有病率が高まる中、医療従事者は費用対効果が高く信頼性の高い治療法を求めており、ビグアナイドの需要は増加の一途をたどっています。さらに、ビグアナイドは糖尿病治療以外にも、アンチエイジング、がん治療、心臓血管疾患予防への応用の可能性を示唆する新たな調査もあり、有望視されています。

ビグアナイドは、メタボリックヘルスの役割を超えて、抗菌特性、特に消毒剤や防腐剤にも広く使用されています。ビグアナイド系化合物であるクロルヘキシジンは、医療用防腐剤、口腔衛生用品、外科用消毒剤の主要成分です。細菌、真菌、ウイルスに対する幅広い抗菌活性により、病院での感染対策やパーソナルケア用途に欠かせないものとなっています。抗生物質耐性への懸念が高まるにつれ、ビグアナイドのような代替抗菌ソリューションへの需要は、製薬、ヘルスケア、消費者衛生市場全体で拡大しています。ビグアナイドは、現在進行中の臨床研究により、新たな治療用途を探求しており、代謝疾患管理と感染予防の両面で重要な要素であり続けています。

技術の進歩は、ビグアナイドベースの治療をどのように強化しているのか？

製剤およびドラッグデリバリーシステムにおける技術革新は、ビグアナイド系治療薬の有効性、バイオアベイラビリティ、安全性プロファイルを著しく向上させています。この分野における最も注目すべき進歩の1つは、徐放性（ER）メトホルミン製剤の開発であり、胃腸の副作用を軽減し、1日複数回投与の必要性を最小限に抑えることで、患者の服薬アドヒアランスを向上させています。これらの製剤は薬物の吸収を高め、より安定したグルコースコントロールを提供するため、長期的な糖尿病管理のための好ましい選択肢となっています。さらに、Na-グルコース共輸送体-2（SGLT2）阻害薬やジペプチジルペプチダーゼ-4（DPP-4）阻害薬とビグアナイドを組み合わせた併用療法の調査により、複雑な代謝疾患を持つ患者の治療成績が改善されつつあります。

もう一つの大きな躍進は、がんや神経変性疾患などの新しい治療領域におけるビグアナイドの探求です。最近の研究では、メトホルミンが細胞のエネルギー代謝を阻害し、腫瘍の増殖を抑えることによって抗がん作用を有することが示唆されています。さらに、前臨床研究では、メトホルミンには神経保護作用があり、アルツハイマー病やその他の神経変性疾患の進行を遅らせる役割を果たす可能性が示唆されています。抗菌剤の分野では、ナノ粒子ベースのデリバリー・システムの進歩により、院内感染の予防や創傷治癒の改善におけるクロルヘキシジンの有効性が高まっています。製薬会社やバイオテクノロジー企業が研究開発への投資を続ける中、ビグアナイド系治療薬は新たな医療用途に拡大し、現代医療における関連性が強まると予想されます。

ビグアナイド市場の成長を牽引する業界動向は？

世界のビグアナイド市場は、糖尿病有病率の上昇、抗菌ソリューションの需要増加、新興治療分野での用途拡大により、着実な成長を遂げています。市場を形成する最も影響力のある動向の一つは、2型糖尿病患者の急増であり、特に新興経済諸国ではライフスタイルの変化や都市化によって代謝異常の発生率が高くなっています。政府やヘルスケア機関が糖尿病管理を優先する中、メトホルミンはその手頃な価格と実証された有効性により、依然として第一選択薬となっています。さらに、予防ヘルスケアが重視されるようになったことで、スクリーニングや早期診断が増加し、ビグアナイド系治療薬の需要をさらに押し上げています。

市場に影響を与えるもう一つの主要動向は、ヘルスケアと消費者の衛生管理における感染制御への注目の高まりです。COVID-19の大流行により、抗菌剤耐性に対する意識が高まり、効果的な消毒剤の必要性が高まったため、病院、歯科治療、個人衛生用品において、クロルヘキシジンのようなビグアナイド系消毒剤の使用が増加しています。さらに、遠隔医療や電子薬局の拡大により、ビグアナイド系薬剤へのアクセスが改善され、市場の継続的な成長が確保されています。個別化医療、特に精密糖尿病治療におけるビグアナイドの探求も、研究者が遺伝子や代謝プロファイルに基づいて治療を最適化する標的療法を開発するにつれて牽引力を増しています。革新的で費用対効果の高いヘルスケアソリューションへの需要が高まり続ける中、ビグアナイド市場は複数の治療および予防用途で拡大が見込まれています。

ビグアナイド市場の将来を形作る主な成長促進要因とは？

ビグアナイド市場の成長は、糖尿病有病率の増加、薬剤調査への投資増加、糖尿病以外の治療領域での用途拡大など、いくつかの要因によってもたらされます。主な成長要因の一つは、現在進行中の世界の糖尿病流行であり、2023年には5億3,700万人以上の成人が糖尿病に罹患すると推定されています。メトホルミンは手ごろな価格と長年にわたる臨床的成功により、特に先進治療へのアクセスが限られている新興市場において、糖尿病管理戦略の重要な要素となっています。さらに、製薬企業は治療効果を高め、副作用を最小限に抑えるために、新しい薬剤の組み合わせや次世代のビグアナイド・アナログを模索しています。

市場を形成するもう一つの重要な促進要因は、抗菌・感染制御ソリューションに対するニーズの高まりです。院内感染（HAI）が公衆衛生上の重大なリスクとなる中、クロルヘキシジンをベースとする防腐剤・消毒剤の需要は増加の一途をたどっています。さらに、抗菌薬耐性に対する意識の高まりから、薬剤耐性病原体に対する有効性を高めたビグアナイド誘導体の研究が進められています。腫瘍学、神経保護、長寿研究におけるビグアナイドの潜在的役割も、バイオテクノロジー企業や製薬企業の関心を高め、新たな投資機会につながっています。科学の進歩により新たな治療用途が次々と開発され、規制当局が適応拡大を支持する中、ビグアナイド市場は持続的な成長を遂げ、代謝医療と抗菌医療の両分野における重要性を確固たるものにしています。

セグメント

タイプ（メトホルミン、フェンホルミン）、流通チャネル（小売薬局流通チャネル、病院流通チャネル、その他流通チャネル）

調査対象企業の例

  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals
  • Intas Pharmaceuticals
  • Lupin Pharmaceuticals, Inc.
  • Merck KGAA
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris, Inc.
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.

AIインテグレーション

検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29554

Global Biguanides Market to Reach US$5.9 Billion by 2030

The global market for Biguanides estimated at US$5.1 Billion in the year 2024, is expected to reach US$5.9 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2024-2030. Metformin, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Phenformin segment is estimated at 1.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 5.0% CAGR

The Biguanides market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 5.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Biguanides Market - Key Trends & Drivers Summarized

Why Are Biguanides a Critical Component in Diabetes and Antimicrobial Treatments?

Biguanides, a class of medications primarily used to treat type 2 diabetes, have remained a cornerstone of diabetes management due to their effectiveness in lowering blood glucose levels and improving insulin sensitivity. Metformin, the most widely prescribed biguanide, has gained global recognition for its role in reducing hepatic glucose production while enhancing peripheral glucose uptake. With the increasing prevalence of type 2 diabetes and metabolic disorders worldwide, the demand for biguanides continues to rise as healthcare providers seek cost-effective and reliable treatment options. Additionally, biguanides have shown promise beyond diabetes treatment, with emerging research suggesting potential applications in anti-aging, cancer therapy, and cardiovascular disease prevention.

Beyond their role in metabolic health, biguanides are also widely used for their antimicrobial properties, particularly in disinfectants and antiseptics. Chlorhexidine, a biguanide-based compound, is a key ingredient in medical-grade antiseptics, oral hygiene products, and surgical disinfectants. Its broad-spectrum antimicrobial activity against bacteria, fungi, and viruses has made it indispensable in hospital infection control and personal care applications. As concerns about antibiotic resistance grow, the demand for alternative antimicrobial solutions like biguanides is expanding across pharmaceutical, healthcare, and consumer hygiene markets. With ongoing clinical research exploring new therapeutic uses, biguanides are positioned to remain a vital component of both metabolic disease management and infection prevention.

How Are Technological Advancements Enhancing Biguanide-Based Treatments?

Innovations in pharmaceutical formulation and drug delivery systems are significantly improving the efficacy, bioavailability, and safety profile of biguanide-based treatments. One of the most notable advancements in this field is the development of extended-release (ER) metformin formulations, which offer better patient adherence by reducing gastrointestinal side effects and minimizing the need for multiple daily doses. These formulations enhance drug absorption and provide more stable glucose control, making them a preferred option for long-term diabetes management. Additionally, research into combination therapies that pair biguanides with sodium-glucose co-transporter-2 (SGLT2) inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors is driving improved treatment outcomes for patients with complex metabolic conditions.

Another major breakthrough is the exploration of biguanides in new therapeutic areas, including oncology and neurodegenerative diseases. Recent studies have suggested that metformin possesses anti-cancer properties by inhibiting cellular energy metabolism and reducing tumor growth. Additionally, preclinical research indicates that biguanides may have neuroprotective effects, potentially playing a role in delaying the progression of Alzheimer’s disease and other neurodegenerative disorders. In the antimicrobial sector, advancements in nanoparticle-based delivery systems are enhancing the effectiveness of chlorhexidine in preventing hospital-acquired infections and improving wound healing. As pharmaceutical and biotech companies continue to invest in research and development, biguanide-based treatments are expected to expand into new medical applications, reinforcing their relevance in modern medicine.

Which Industry Trends Are Driving Growth in the Biguanides Market?

The global biguanides market is experiencing steady growth due to rising diabetes prevalence, increasing demand for antimicrobial solutions, and expanding applications in emerging therapeutic fields. One of the most influential trends shaping the market is the surge in type 2 diabetes cases, particularly in developing economies where lifestyle changes and urbanization have led to a higher incidence of metabolic disorders. With governments and healthcare organizations prioritizing diabetes management, metformin remains a first-line therapy due to its affordability and proven efficacy. Additionally, the growing emphasis on preventive healthcare has led to increased screening and early diagnosis, further driving demand for biguanide-based treatments.

Another key trend influencing the market is the rising focus on infection control in healthcare and consumer hygiene. The COVID-19 pandemic heightened awareness of antimicrobial resistance and the need for effective disinfectants, leading to increased use of biguanide-based antiseptics like chlorhexidine in hospitals, dental care, and personal hygiene products. Moreover, the expansion of telemedicine and e-pharmacies has improved access to biguanide medications, ensuring continued market growth. The exploration of biguanides in personalized medicine, particularly in precision diabetes care, is also gaining traction as researchers develop targeted therapies that optimize treatment based on genetic and metabolic profiles. As the demand for innovative and cost-effective healthcare solutions continues to rise, the biguanides market is expected to expand across multiple therapeutic and preventive applications.

What Are the Key Growth Drivers Shaping the Future of the Biguanides Market?

The growth in the biguanides market is driven by several factors, including increasing diabetes prevalence, rising investments in drug research, and expanding applications in non-diabetes therapeutic areas. One of the primary growth drivers is the ongoing global diabetes epidemic, with over 537 million adults estimated to have diabetes in 2023. The affordability and long-standing clinical success of metformin make it a critical component of diabetes management strategies, particularly in emerging markets with limited access to advanced therapies. Additionally, pharmaceutical companies are exploring novel drug combinations and next-generation biguanide analogs to enhance therapeutic efficacy and minimize side effects.

Another key driver shaping the market is the growing need for antimicrobial and infection control solutions. With hospital-acquired infections (HAIs) posing a significant public health risk, the demand for chlorhexidine-based antiseptics and disinfectants continues to rise. Furthermore, the increasing awareness of antimicrobial resistance has prompted research into biguanide derivatives with enhanced efficacy against drug-resistant pathogens. The potential role of biguanides in oncology, neuroprotection, and longevity research is also driving interest from biotech and pharmaceutical firms, leading to new investment opportunities. As scientific advancements continue to unlock new therapeutic applications and regulatory agencies support expanded indications, the biguanides market is poised for sustained growth, solidifying its importance in both metabolic and antimicrobial medicine.

SCOPE OF STUDY:

The report analyzes the Biguanides market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Metformin, Phenformin); Distribution Channel (Retail Pharmacies Distribution Channel, Hospitals Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals
  • Intas Pharmaceuticals
  • Lupin Pharmaceuticals, Inc.
  • Merck KGAA
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris, Inc.
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Biguanides - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Diabetes Prevalence Throws the Spotlight on Biguanides as a First-Line Therapeutic Class
    • Growing Demand for Cost-Effective Antidiabetic Drugs Drives Widespread Use of Metformin-Based Biguanides
    • Increased Focus on Metabolic Health and Pre-Diabetes Management Expands Addressable Market Opportunity for Biguanide Compounds
    • Scientific Advancements in Repurposing Biguanides for Cancer, Aging, and Cardiovascular Health Strengthen Long-Term Growth Prospects
    • Regulatory Endorsement of Metformin as a Gold-Standard Treatment Drives Continued Global Adoption
    • Emerging Research on Biguanides in Geroprotection and Longevity Science Spurs New Therapeutic Applications
    • Surge in Demand for Antimicrobial Agents Drives Biguanide Usage in Hospital-Grade Disinfectants and Antiseptics
    • Expansion of Personal Hygiene and Surface Disinfection Markets Strengthens the Business Case for Biguanide-Based Biocides
    • Growing Emphasis on Infection Control in Healthcare Facilities Fuels Demand for Biguanide Antiseptics Like Chlorhexidine
    • Interest in Combination Therapies and Drug Synergies Enhances Use of Biguanides in Multimodal Treatment Regimens
    • Rising Geriatric Population and Polypharmacy Trends Sustain Long-Term Demand for Well-Tolerated Biguanide Drugs
    • Low Cost and High Therapeutic Index of Biguanides Support Their Role in Essential Drug Lists and Public Health Programs
    • Emerging Interest in Biguanides for Weight Management and Insulin Sensitivity Strengthens Consumer and Clinical Demand
    • Increasing Pharmaceutical R&D Investments Drive Innovation in Modified-Release and Combination Formulations of Biguanides
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biguanides Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biguanides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Biguanides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Metformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Metformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Metformin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phenformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Phenformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Phenformin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Biguanides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Biguanides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Biguanides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Biguanides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Biguanides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Biguanides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Biguanides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION